PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, cementing its position as a leading player in the industry. Backed by prominent investors such as Eight Roads, FIL Capital, and F-Prime, PlasmaGen has now raised over ₹600 crore to date, underscoring the confidence of investors in its growth potential.
The funding round is a testament to PlasmaGen’s commitment to innovation and excellence in the field of plasma fractionation. The company operates one of India’s five plasma fractionation facilities near Bengaluru, which is a critical component in the production of life-saving therapies. Plasma fractionation is the process of separating plasma into its various components, such as albumin, immunoglobulins, and clotting factors, which are then used to manufacture therapies for a range of diseases, including hemophilia, immunodeficiency disorders, and infectious diseases.
PlasmaGen’s state-of-the-art facility is equipped with cutting-edge technology and staffed by a team of experienced professionals who are dedicated to ensuring the highest standards of quality and safety. The company’s products are used by hospitals and healthcare providers across India, and its commitment to delivering high-quality therapies has earned it a reputation as a trusted partner in the industry.
The investment by ViNS Bioproducts is a strategic move that will enable PlasmaGen to expand its operations and increase its production capacity. The company plans to use the funds to upgrade its facility, invest in research and development, and enhance its marketing and distribution capabilities. This will enable PlasmaGen to tap into the growing demand for plasma-derived therapies in India and overseas, and to consolidate its position as a leading player in the industry.
The Indian biotechnology sector has been witnessing rapid growth in recent years, driven by government initiatives, increasing investments, and a growing demand for innovative therapies. The sector is expected to reach $150 billion by 2025, and plasma fractionation is one of the key areas that is expected to drive growth. PlasmaGen is well-positioned to capitalize on this trend, given its expertise, infrastructure, and commitment to quality.
The company’s backers, including Eight Roads, FIL Capital, and F-Prime, are prominent investors in the biotechnology sector, with a track record of supporting innovative companies that have the potential to make a significant impact. Their investment in PlasmaGen is a vote of confidence in the company’s management team, its technology, and its growth prospects.
In conclusion, the funding round led by ViNS Bioproducts is a significant milestone for PlasmaGen Biosciences, and a testament to the company’s potential for growth and innovation. With its strong foundation, cutting-edge technology, and commitment to quality, PlasmaGen is poised to play a leading role in the Indian biotechnology sector, and to make a meaningful contribution to the development of life-saving therapies.
As the Indian biotechnology sector continues to evolve, it will be interesting to see how PlasmaGen navigates the challenges and opportunities that lie ahead. With its strong backing, expertise, and infrastructure, the company is well-positioned to capitalize on the growing demand for plasma-derived therapies, and to consolidate its position as a leading player in the industry.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
